Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARISOPRODOL COMPOUND vs POMALYST
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Carisoprodol is a centrally acting muscle relaxant that acts as a prodrug for meprobamate, a barbiturate-like compound with sedative and anxiolytic properties. Its mechanism is thought to involve GABA-A receptor modulation and depression of polysynaptic reflexes in the spinal cord and reticular formation. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia by mimicking endogenous endorphins.
Pomalidomide is an immunomodulatory agent with antineoplastic activity. It inhibits proliferation and induces apoptosis of hematopoietic tumor cells. Additionally, it enhances T-cell- and natural killer (NK) cell-mediated immunity and inhibits angiogenesis by blocking the production of pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b FGF). The exact mechanism of its immunomodulatory and antineoplastic effects is not fully understood.
Relief of discomfort associated with acute, painful musculoskeletal conditions,As an adjunct to rest, physical therapy, and other measures
Multiple myeloma (in combination with dexamethasone) in patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy,AIDS-related Kaposi sarcoma (in patients with AIDS-related Kaposi sarcoma who have failed highly active antiretroviral therapy [HAART] or are intolerant to HAART)
1-2 tablets (carisoprodol 200 mg/aspirin 325 mg) orally 4 times daily.
4 mg orally once daily on days 1-21 of repeated 28-day cycles in combination with dexamethasone, for multiple myeloma; for Kaposi sarcoma, 5 mg orally once daily on days 1-21 of 28-day cycles.
Carisoprodol has a terminal elimination half-life of approximately 1.5–2 hours; its active metabolite meprobamate has a half-life of 9–12 hours, which may lead to prolonged effects with chronic use.
Terminal elimination half-life is approximately 7.5 hours in patients with multiple myeloma, allowing for once-daily dosing without accumulation at steady state.
Carisoprodol is metabolized by CYP2C19 to meprobamate (active metabolite). Aspirin is hydrolyzed by esterases in the liver and plasma to salicylic acid, which is further conjugated. Codeine is metabolized by CYP2D6 to morphine (active) and by CYP3A4 to norcodeine.
Pomalidomide is primarily metabolized by cytochrome P450 (CYP) 1A2 and CYP3A4. It also undergoes hydroxylation and subsequent glucuronidation. Minor pathways include CYP2C19 and CYP2D6.
Carisoprodol is primarily metabolized in the liver, with about 50% excreted renally as unchanged drug and metabolites; the major metabolite meprobamate is also renally excreted. Fecal excretion is negligible (<2%).
Approximately 73% of radiolabeled pomalidomide is excreted in urine (primarily as metabolites, with <2% as unchanged drug) and 15% in feces. Renal clearance is the major elimination pathway.
Carisoprodol is approximately 60% bound to plasma proteins, mainly albumin.
33% bound to human plasma proteins, predominantly to albumin.
Volume of distribution is approximately 0.6–0.8 L/kg, indicating distribution into total body water.
Apparent volume of distribution is approximately 120 L (1.7 L/kg for a 70 kg individual), indicating extensive tissue distribution beyond plasma volume.
Oral bioavailability is nearly complete (close to 100%) due to rapid and extensive absorption.
Oral bioavailability is approximately 73% (range: 66-81%). Administration with a high-fat meal decreases Cmax by 36% and AUC by 26% relative to fasting; therefore, take on an empty stomach.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). No specific dose adjustment for mild-moderate impairment; use caution.
For Cr Cl ≥60 m L/min: no adjustment; Cr Cl 30-59 m L/min: reduce dose to 3 mg once daily; Cr Cl <30 m L/min: not recommended (no dose established).
Contraindicated in severe hepatic impairment (Child-Pugh class C). For moderate impairment, reduce dose or increase interval; specific guidelines not established.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 3 mg once daily; Child-Pugh C: reduce dose to 2 mg once daily.
Not recommended for pediatric patients due to aspirin content and risk of Reye syndrome.
Safety and efficacy not established in pediatric patients; no standard dosing.
Initiate at lowest effective dose; monitor for CNS depression, falls, and aspirin-related bleeding. Avoid in patients ≥65 years due to risks of dizziness, sedation, and GI bleeding.
No specific dose adjustment based on age alone; monitor for toxicity and adjust based on renal function as per adult recommendations.
None
WARNING: EMBRYO-FETAL TOXICITY and VENOUS AND ARTERIAL THROMBOEMBOLISM. Pomalidomide is contraindicated in pregnant women because it can cause severe birth defects or death to an unborn baby. Females of reproductive potential must avoid pregnancy during treatment and for at least 4 weeks after the last dose. Pomalidomide is only available through a restricted distribution program called the POMALYST REMS program. Additionally, pomalidomide significantly increases the risk of venous and arterial thromboembolism (including deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke). Thromboprophylaxis is recommended.
Risk of dependence, abuse, and withdrawal with carisoprodol and codeine,CYP2D6 ultrarapid metabolizers may have morphine toxicity from codeine,Reye's syndrome risk in children with viral illness (aspirin),GI bleeding risk with aspirin,Respiratory depression with codeine,Sedation and impaired motor function,Hepatic impairment,Renal impairment
Embryo-fetal toxicity: Can cause fetal harm; females of reproductive potential must use effective contraception and avoid pregnancy. Males should avoid donating sperm.,Thromboembolism: Increased risk of venous and arterial thromboembolic events; thromboprophylaxis recommended.,Hematologic toxicity: Neutropenia and thrombocytopenia are common; monitor blood counts regularly.,Hepatotoxicity: Can cause elevated liver enzymes and hepatic failure; monitor liver function tests.,Cardiac toxicity: Increased risk of heart failure, myocardial infarction, and atrial fibrillation.,Hypersensitivity reactions: Including angioedema, Stevens-Johnson syndrome, and toxic epidermal necrolysis; discontinue if severe reaction occurs.,Tumor lysis syndrome: Monitor patients at risk.,Interference with oral contraceptives: May reduce efficacy of oral contraceptives; consider additional non-hormonal contraception.
Hypersensitivity to carisoprodol, meprobamate, aspirin, codeine, or any component,Porphyria,Acute intermittent porphyria,Children with viral illness (aspirin) due to Reye's syndrome risk,Breastfeeding (codeine),Severe renal or hepatic impairment,GI bleeding or peptic ulcer disease (aspirin),Concurrent use of MAOIs or within 14 days,Respiratory depression (codeine)
Pregnancy,Hypersensitivity to pomalidomide or any component of the formulation
Avoid alcohol and grapefruit juice. Alcohol increases CNS depression and risk of hepatotoxicity. Grapefruit juice may inhibit metabolism, leading to increased levels and toxicity.
Avoid grapefruit and grapefruit juice due to potential CYP3A4 interaction. No specific dietary restrictions otherwise; take with or without food. Maintain adequate hydration to prevent tumor lysis syndrome. Avoid alcohol due to increased risk of liver toxicity.
Carisoprodol is a pregnancy category C drug. Data from animal studies are insufficient or show adverse effects, but no adequate human studies exist. There is a potential risk of fetal harm if used during the first trimester due to possible neural tube defects based on limited reports. In the second and third trimesters, maternal use may cause neonatal withdrawal symptoms (e.g., irritability, feeding difficulties) and respiratory depression if used near term. Carisoprodol is not recommended during pregnancy unless benefit outweighs risk.
Pomalidomide is an immunomodulatory drug (IMi D) structurally related to thalidomide, a known human teratogen. It is contraindicated in pregnancy due to high risk of severe birth defects or embryo-fetal death. Fetal exposure during any trimester can cause major congenital malformations, including limb defects, craniofacial anomalies, and cardiovascular abnormalities. Use in females of reproductive potential requires negative pregnancy testing before treatment, and use of two effective contraceptive methods during therapy and for 4 weeks after discontinuation. Pregnancy testing frequency: weekly during first month, then every 2-4 weeks if regular cycles, or every 2 weeks if irregular cycles.
Carisoprodol is excreted into human breast milk. The milk-to-plasma (M/P) ratio is approximately 2-4 based on small studies. An infant would receive a weight-adjusted dose of about 4-8% of the maternal dose, which may cause sedation, drowsiness, or irritability in the neonate. Breastfeeding is not recommended during carisoprodol use, especially in premature infants or those with hepatic impairment. If used, monitor infant for signs of CNS depression.
It is unknown whether pomalidomide is excreted in human milk. Due to the potential for serious adverse reactions in breastfeeding infants, women should not breastfeed during treatment with pomalidomide. No M/P ratio is available.
No specific dosing adjustments for carisoprodol are established in pregnancy. However, due to increased plasma volume and altered hepatic metabolism in pregnancy, the drug's half-life may be reduced. Clinical monitoring for efficacy and maternal side effects (e.g., drowsiness, dizziness) is recommended. Use the lowest effective dose for the shortest duration. Consider avoidance of the compound formulation with aspirin or other NSAIDs, which have additional risks.
Pomalidomide is contraindicated in pregnancy; no dose adjustments are applicable because use during pregnancy is not recommended. If exposure occurs, the manufacturer recommends immediate discontinuation and referral to a teratology specialist. No pharmacokinetic studies on pregnancy-related dose adjustments exist.
Carisoprodol is metabolized to meprobamate, a controlled substance with abuse potential; use cautiously in patients with history of substance abuse. Combination with other CNS depressants (e.g., alcohol, benzodiazepines) increases sedation risk. Limit use to 2-3 weeks due to lack of efficacy beyond that and risk of dependence. Avoid in patients with porphyria because carisoprodol may be porphyrinogenic.
Pomalidomide is an immunomodulatory drug used in multiple myeloma after prior therapies including lenalidomide and bortezomib. Requires baseline and periodic CBCs, liver and renal function tests. High risk for venous thromboembolism; prophylaxis with aspirin or anticoagulation recommended. Contraindicated in pregnancy due to severe teratogenicity, necessitating REMS program. Dose adjust for renal impairment (Cr Cl <45 m L/min) and hepatic impairment (Child-Pugh C). Monitor for tumor lysis syndrome, especially in patients with high tumor burden.
This medication may cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how it affects you.,Do not consume alcohol or other CNS depressants while taking this drug.,Take only as prescribed; do not increase dose or frequency. This drug has abuse potential.,Inform your doctor if you have a history of drug or alcohol abuse, seizures, or liver/kidney disease.,Do not use for longer than 2-3 weeks unless directed by your doctor.
Pomalidomide is a chemotherapy drug that helps treat multiple myeloma by targeting cancer cells.,Do not take if pregnant or planning to become pregnant; use effective contraception during treatment and for 4 weeks after stopping.,Do not breastfeed while taking pomalidomide.,Report any signs of bleeding, bruising, fever, shortness of breath, or chest pain immediately.,Take exactly as prescribed; do not break, chew, or crush capsules; swallow whole with water.,May cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Avoid live vaccines while on this medication.,Store at room temperature away from moisture and heat.,Keep all appointments for blood tests and other monitoring.,Inform all healthcare providers that you are taking pomalidomide.
"The co-administration of pentobarbital, a barbiturate and potent CYP3A4 inducer, with carisoprodol, a prodrug that is metabolized to its active form, meprobamate, via CYP2C19, may lead to reduced plasma concentrations of meprobamate due to pentobarbital-induced upregulation of CYP2C19, potentially diminishing the sedative and muscle relaxant effects of carisoprodol. However, pentobarbital also acts as a central nervous system (CNS) depressant, and additive CNS depression can occur, increasing the risk of excessive sedation, respiratory depression, and impairment of psychomotor function. Clinical outcomes may include altered therapeutic efficacy of carisoprodol and heightened risk of CNS and respiratory adverse effects."
"Carisoprodol, a centrally acting skeletal muscle relaxant, is metabolized primarily by CYP2C19 to its active metabolite meprobamate. Isoniazid, a first-line antitubercular agent, is a known inhibitor of CYP2C19. When coadministered, isoniazid can decrease the metabolism of carisoprodol, leading to increased plasma concentrations of both carisoprodol and meprobamate. This elevation raises the risk of dose-related adverse effects such as sedation, dizziness, and respiratory depression, and may prolong the duration of muscle relaxant action."
"The combination of sulpiride, an atypical antipsychotic with dopamine D2 receptor antagonism and mild serotonin 5-HT4 agonist properties, and carisoprodol, a centrally acting muscle relaxant metabolized to meprobamate (a barbiturate-like sedative-hypnotic), can result in additive central nervous system (CNS) depression, including sedation, dizziness, and psychomotor impairment. Additionally, both drugs may lower the seizure threshold, increasing the risk of seizures. Sulpiride can also prolong the QT interval, and carisoprodol's sedative effects may mask or exacerbate this cardiotoxicity, potentially leading to ventricular arrhythmias such as torsade de pointes."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARISOPRODOL COMPOUND vs POMALYST, answered by our medical review team.
CARISOPRODOL COMPOUND is a Skeletal Muscle Relaxant that works by Carisoprodol is a centrally acting muscle relaxant that acts as a prodrug for meprobamate, a barbiturate-like compound with sedative and anxiolytic properties. Its mechanism is thought to involve GABA-A receptor modulation and depression of polysynaptic reflexes in the spinal cord and reticular formation. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia by mimicking endogenous endorphins.. POMALYST is a Immunomodulatory Agent that works by Pomalidomide is an immunomodulatory agent with antineoplastic activity. It inhibits proliferation and induces apoptosis of hematopoietic tumor cells. Additionally, it enhances T-cell- and natural killer (NK) cell-mediated immunity and inhibits angiogenesis by blocking the production of pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b FGF). The exact mechanism of its immunomodulatory and antineoplastic effects is not fully understood.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARISOPRODOL COMPOUND and POMALYST depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARISOPRODOL COMPOUND is: 1-2 tablets (carisoprodol 200 mg/aspirin 325 mg) orally 4 times daily.. The standard adult dose of POMALYST is: 4 mg orally once daily on days 1-21 of repeated 28-day cycles in combination with dexamethasone, for multiple myeloma; for Kaposi sarcoma, 5 mg orally once daily on days 1-21 of 28-day cycles.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARISOPRODOL COMPOUND and POMALYST in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARISOPRODOL COMPOUND is classified as Category A/B. Carisoprodol is a pregnancy category C drug. Data from animal studies are insufficient or show adverse effects, but no adequate human studies exist. There is a potential risk of fe. POMALYST is classified as Category C. Pomalidomide is an immunomodulatory drug (IMiD) structurally related to thalidomide, a known human teratogen. It is contraindicated in pregnancy due to high risk of severe birth de. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.